Real-World Outcomes of Tisagenlecleucel in Patients Younger Than 3 Years With Acute Lymphoblastic Leukemia
Real-world data confirmed the efficacy and safety profiles of tisagenlecleucel in patients with relapsed/refractory ALL younger than 3 years old.